Inauguration of the New Viking Malt Production Plant in Lahti, Finland
23.5.2023 14:00:00 EEST | Business Wire | Press release
In Lahti, Finland on 23rd of May 2023 Viking Malt's new malting plant was officially inaugurated with a festive opening ceremony.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005582/en/
The capacity of the new malting plant is about 85 000 t/y and it replaces the old plant in Lahti. The new plant enables production of base malts, a wide selection of specialty malts as well as Sprau, Viking Malt's malted faba bean innovation. (Photo: Business Wire)
The capacity of the new malting plant is about 85 000 t/y and it replaces the old plant in Lahti. The new plant enables the production of base malts, a wide selection of specialty malts as well as Sprau, Viking Malt's malted faba bean innovation. In addition, the modern factory supports the sustainability strategy of Viking Malt with improved energy efficiency and a better working environment from a health and safety point of view.
“Building this new plant was a true team effort”, says the CEO Kasper Madsen, involving not only resources from the Viking Malt but also a range of suppliers and the support of our customers. Managing such a complex project in times disrupted by both a pandemic and a war requires strong and reliable partners.”
Pär-Gustaf Relander, owner and Chairman of the Board says that opening a new plant in Lahti, Finland, is a significant milestone in Viking Malt's history and a step forward in the company's long term strategy of building a sustainable business for the generations to come.
Viking Malt sells its products globally to the brewing, distilling and food industries. The company has a long history and is today owned by Polttimo representing the 5th generation of the same family, and Lantmännen. Polttimo is celebrating its 140 years anniversary this year. Throughout its history, it has survived and thrived by adaptability to changes in the operating environment, and a strong focus on quality and innovation.
Today, Viking Malt Group has production in 5 countries: Finland, Sweden, Denmark, Lithuania as well as two plants in Poland. The production capacity is 610 000 t/y and the turnover of the group is appr. 300 million euros. The group employs appr. 260 employees. Viking Malt is the largest malting company in the Baltic Rim, 5th largest in Europe and 9th in the world. It is amongst the leading companies in specialty malts in the global market. Viking Malt Group is owned by Polttimo (62,5 %) and Svenska Lantmännen (37,5 %).
More info about the company and products: www.vikingmalt.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005582/en/
Contact information
Additional information:
Pär-Gustaf Relander, Chairman of the Board, +358 50 552 3955
Kasper Madsen, CEO Viking Malt Group, +45 22 14 20 10
Pia Valve, VP HR and Communications Viking Malt Group +358 40 7700090
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom